Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry
ConclusionsCD146 is a novel mediator of both angiogenesis and vasculogenic mimicry in uveal melanoma. Its antibody AA98 has the potency to be developed as a new antibody drug for treating uveal melanoma. Our results warrant further assessment of CD146 as a potential target to improve therapeutic management of uveal melanoma in a clinical setting.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Eye Cancers | Eyes | Melanoma | Skin Cancer | Uveal Melanoma | Vitamin A